Abstract:Rabies is fatal in nearly 100% of cases, making post-exposure prophylaxis (PEP) a required measure for preventing mortality. Currently, the rabies vaccination regimen requires at least three to five clinic visits, with vaccination and transportation costs being very high. This study assessed the safety and efficacy of the 2-1 intramuscular (IM) regimen for rabies immunization with the goal of making rabies prophylaxis more economical.One-hundred and eighty-one subjects were divided into two groups: 79 subjects in test group A and 102 subjects in control group B. 2-1 IM regimen was chosen for group A and the Essen regimen was adopted for group B. Serum samples were also collected at D0, D7, D14, D45, D180, and D360 to determine the rabies serum neutralizing antibody by rapid luorescent focus inhibition test (RFFIT).There was no significant difference between groups A and B with respect to the rate of adverse events following each vaccination. Nine-hundred and nineteen blood samples were obtained. At D0 (prior to immunization), all study subjects exhibited a geometric mean titer (GMT)<0.05 IU/ml. On D14, all study subjects exhibited NAb titers>0.5 IU/ml; titers above 0.5 IU/ml were maintained in both groups through D45 and D180 before gradually declining. The percentage of subjects positive for NAbs in group A and group B on D7 were 88.6% and 87.3%, respectively, which was not statistically different (P=0.545). On D360, the percentage of subjects positive for NAbs in group A and group B were 93.9% and 100% (P<0.01), respectively. During the study, the GMT was highest for both groups on D14 (21.90 IU/ml, group A; 19.93 IU/ml, group B) (P=0.045). On D45, the GMTs were 8.28 IU/ml (group A) and 7.89 IU/ml (group B) (P=0.037). On D7, D180, and D360, there were no statistically significant differences between the two groups with respect to the GMT.The 2-1 IM regimen demonstrates the same safety and efficacy as the Essen regimen. The use of the 2-1 IM regimen could not only reduce the personal economic burdens of rabies immunization but also improve rabies immunization rates through fewer office visits and compliance with immunization procedures. However, further evaluation is needed before a major recommendation can be made.

Comparing Recombinant Human Rabies Monoclonal Antibody (Ormutivimab) with Human Rabies Immunoglobulin (HRIG) for Postexposure Prophylaxis: A Phase 3, Randomized, Double-Blind, Non-inferiority Trial

Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase IIb randomized, double-blind, parallel-controlled study

Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects

Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models

Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus

Development of Human Monoclonal Antibodies With Broad Reactivity for Rabies Postexposure Prophylaxis

Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free, Compared With Two Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized Controlled Phase III Trial

A Randomized, Double-Blind, Controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of a Lyophilized Human Rabies Vaccine (Vero Cells) in Healthy Participants Aged 10–60 Years Following Essen and Zagreb Vaccination Procedures

Assessing the Safety of a Novel Monoclonal Antibody Cocktail for Postexposure Prophylaxis in Category III Animal Exposures

Safety, immunogenicity and immune-persistence of a lyophilized human rabies vaccine (Vero cells) under Zagreb and Essen regimens: a randomized, open-label, controlled phase III clinical trial in healthy participants aged 10–60 years in China

Rabbit Anti-Rabies Immunoglobulins Production and Evaluation

Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis

Post-Marketing Surveillance of the World's First Novel Cocktail of Rabies Monoclonal Antibodies: TwinRab™ in Real \-World Setting

Making Rabies Prophylaxis More Economical

A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis

Immunogenicity and immune persistence of Zagreb 2-1-1 regimen of rabies vaccine in Chinese healthy individuals: A randomized, parallel-controlled of homologous vaccine with different immune procedure study

Immunogenicity Persistence of Different Immunization Regimens of Rabies Vaccine in the 10–60 Years Age Group: A Follow-Up Report Based on Phase III Clinical Trial

Immunogenicity of 4-dose Essen intramuscular regimen for rabies post-exposure prophylaxis: A multi-center cross-sectional study in China

Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults

Characterization of a human–mouse chimeric monoclonal antibody targeting rabies virus glycoprotein

Application of a caprylate/chromatography purification process for production of a high potency rabies immune globulin from pooled human plasma